Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Capital Expenditures (2020 - 2025)

Lyell Immunopharma (LYEL) has disclosed Capital Expenditures for 6 consecutive years, with $304000.0 as the latest value for Q4 2025.

  • Quarterly Capital Expenditures fell 31.07% to $304000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $780000.0 through Dec 2025, up 68.1% year-over-year, with the annual reading at $780000.0 for FY2025, 68.1% up from the prior year.
  • Capital Expenditures hit $304000.0 in Q4 2025 for Lyell Immunopharma, down from $467000.0 in the prior quarter.
  • In the past five years, Capital Expenditures ranged from a high of $60.1 million in Q4 2021 to a low of -$38.2 million in Q3 2021.
  • Historically, Capital Expenditures has averaged $4.7 million across 5 years, with a median of $386000.0 in 2024.
  • Biggest five-year swings in Capital Expenditures: tumbled 952.79% in 2021 and later surged 1664.0% in 2024.
  • Year by year, Capital Expenditures stood at $60.1 million in 2021, then crashed by 92.37% to $4.6 million in 2022, then plummeted by 99.45% to $25000.0 in 2023, then soared by 1664.0% to $441000.0 in 2024, then plummeted by 31.07% to $304000.0 in 2025.
  • Business Quant data shows Capital Expenditures for LYEL at $304000.0 in Q4 2025, $467000.0 in Q3 2025, and -$237000.0 in Q2 2025.